loader2
Login Open ICICI 3-in-1 Account
IPOLogoImag

EMCURE PHARMACEUTICALS IPO

IPO Details

-
-
14 Shares
₹ 14,112
₹ 960 – 1008
₹ Up to 1952.03 Cr

Issue timeline

  • -
  • 08-Jul-2024
  • 09-Jul-2024
  • 09-Jul-2024
  • 10-Jul-2024

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

- One of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas
- Research and development (“R&D”) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics
- The 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT September 2023
- The largest pharmaceutical company in the gynecology and human immunodeficiency virus (“HIV”) antivirals therapeutic areas in India in terms of Domestic Sales for MAT September 2023 (Source: CRISIL Report)

Strengths & Risks

Strengths (3)

Well-placed to Leverage Leading Position in the Domestic Market

They are focused on the domestic market, with sales in India contributing to 50.84% and 53.16% of their total revenue from operations for the six months ended Sep 30, 2023 and the FY23, respectively. Their strong position in a number of therapeutic areas such as gynecology, cardiovascular, blood-related, pain and analgesics and oncology/anti-neoplastics has been driven by differentiated product portfolio and first to market product launches (source: Company DRHP)

Risks (2)

There are outstanding legal proceedings involving their company, directors, promoters, subsidiaries and their group company, Heritage

There are outstanding legal proceedings involving company, directors, promoters and their subsidiaries. These proceedings are pending at different levels of adjudication before various courts, tribunals and arbitrators, from which further liability may arise. There is one civil case outstanding against their Group Company, Heritage, the outcome of which could have a material impact on their company. (Source: Company DRHP)

Financials

Industry Overview

- Global pharmaceutical market to grow at steady 4.5-5% CAGR from 2022 to 2027 : Global pharmaceutical market has grown at a CAGR of 5% from approximately US$1,135 billion in CY17 to approximately US$1,457 billion in CY22. After showing strong growth in CY21 and 22 on account of pent-up demand, the market is expected to moderate in the CY23. However, It is expected to sustain 4.5-5% CAGR growth over the next five years from 2022 to 2027 to reach approximately US$1,750 to US$1,800 billion in CY27

 

- Biopharmaceutical industry share to touch approximately 35-37% globally by 2027: The global biopharma industry has significantly outperformed the conventional pharmaceuticals segment over the past few years.CRISIL expects the performance of the biopharma segment to continue, primarily driven by the biologics segment although there is expected to be some moderation in growth owing to the biosimilar launches in the regulated markets.

Emcure Pharmaceuticals IPO FAQs

What is the minimum lot size and investment required for Emcure Pharma?

The lot size is 14 shares and minimum investment required is Rs.14,112 for Emcure Pharma IPO

Emcure Pharmaceuticals IPO is mainboard IPO of issue size up to Rs.1952.03 Crores

Emcure Pharmaceuticals IPO issue dates are from 03rd – 05th July, 2024.

The allotment date is 08th July, 2024 and listing date is 10th July, 2024 for Emucre Pharma IPO

Head to IPO section on ICICI Direct website and select Emcure Pharmaceuticals IPO. Enter and submit bid details and then click on proceed to apply once details are verified. It’s that simple!!

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.